G1 Therapeutics, Inc. (GTHX) Operating Income (Loss) USD 2016 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
G1 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2024.
  • G1 Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$9.05 M, a 64.9% increase year-over-year.
  • G1 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$22.8 M, a 80.2% increase year-over-year.
  • G1 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$39.5 M, a 71% increase from 2022.
  • G1 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$136 M, a 4.41% increase from 2021.
  • G1 Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$142 M, a 47.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$22.8 M -$9.05 M +$16.7 M +64.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 -$39.5 M -$8.93 M +$22 M +71.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$61.5 M -$16.4 M +$5.18 M +24% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 -$66.7 M $11.5 M +$48.5 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$115 M -$25.7 M +$21 M +45% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 -$136 M -$30.9 M +$6.7 M +17.8% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-01
Q3 2022 -$143 M -$21.5 M +$19.6 M +47.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$162 M -$37 M +$1.23 M +3.22% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$164 M -$46.8 M -$21.2 M -83.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$142 M -$37.6 M -$13.5 M -56% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$129 M -$41.1 M -$31.4 M -322% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-01
Q2 2021 -$97.6 M -$38.2 M -$7.37 M -23.9% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-01
Q1 2021 -$90.2 M -$25.5 M +$6.29 M +19.8% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-01
Q4 2020 -$96.5 M -$24.1 M +$12.5 M +34.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-23
Q3 2020 -$109 M -$9.75 M +$24.3 M +71.4% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-23
Q2 2020 -$133 M -$30.8 M +$1.76 M +5.41% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-23
Q1 2020 -$135 M -$31.8 M -$5.94 M -23% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-23
Q4 2019 -$129 M -$36.6 M -$10.5 M -40.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 -$119 M -$34 M -$13.2 M -63.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 -$105 M -$32.6 M -$10.9 M -50.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 -$94.4 M -$25.9 M -$5.16 M -24.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 -$89.3 M -$26.1 M -$8.8 M -50.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$80.5 M -$20.8 M -$4.89 M -30.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$75.6 M -$21.7 M -$6.27 M -40.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$69.3 M -$20.7 M -$8.35 M -67.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$61 M -$17.3 M -$6.88 M -66.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$54.1 M -$15.9 M -$9.32 M -141% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$44.8 M -$15.4 M -$7.95 M -107% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$36.8 M -$12.4 M -$6.43 M -108% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$30.4 M -$10.4 M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-21
Q3 2016 -$6.61 M Jul 1, 2016 Sep 30, 2016 10-K 2018-02-21
Q2 2016 -$7.43 M Apr 1, 2016 Jun 30, 2016 10-K 2018-02-21
Q1 2016 -$5.95 M Jan 1, 2016 Mar 31, 2016 10-K 2018-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.